Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Dec;74(4):589-93.

1,25(OH)2D3 regulates c-myc mRNA levels in tonsillar T lymphocytes

Affiliations

1,25(OH)2D3 regulates c-myc mRNA levels in tonsillar T lymphocytes

R Karmali et al. Immunology. 1991 Dec.

Abstract

The effects of 1,25(OH)2D3 on proliferation, c-myc mRNA levels and 1,25(OH)2D3 receptor expression in activated tonsillar T lymphocytes were studied. Activation of resting T cells with phytohaemagglutinin (PHA) for 72 hr led to an increase in proliferation, c-myc mRNA levels and to induction of 1,25(OH)2D3 receptor expression. However, when activation was carried out in the presence of 1,25(OH)2D3, there was inhibition of PHA-stimulated proliferation and c-myc mRNA levels. Increased cell proliferation, c-myc mRNA expression and 1,25(OH)2D3 receptor number were also observed, albeit to a lesser extent, when T cells were stimulated by phorbol myristate acetate (PMA), anti-CD3 antibody or A23187. However, in these cases 1,25(OH)2D3 was unable to prevent increased proliferation or c-myc mRNA expression. PMA and anti-CD3 used in combination produced similar or greater changes in proliferation, c-myc mRNA levels, 1,25(OH)2D3 receptor expression and responsiveness to the hormone when compared to PHA alone. Thus the inhibition of c-myc expression in activated T lymphocytes by 1,25(OH)2D3 can be related to its anti-proliferative effects. Moreover this inhibition seems to be dependent on the level of 1,25(OH)2D3 receptor expression, which in turn appears to be related to the degree of cell activation.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol. 1985 Oct;135(4):2279-86 - PubMed
    1. J Clin Endocrinol Metab. 1983 Dec;57(6):1308-10 - PubMed
    1. J Endocrinol. 1989 Oct;123(1):137-42 - PubMed
    1. Cell. 1989 Oct 6;59(1):15-20 - PubMed
    1. J Mol Endocrinol. 1989 Jul;3(1):43-8 - PubMed

Publication types

LinkOut - more resources